Caren van Roekel

92 Chapter 3 TABLE 1. Overview of literature (continued) First author, year Treatment arm Control arm n (Y-RE/ other) Primary tumor(s) RE approach Questionnaires Scale range Timing Outcome Van Hazel, 2004 (21) Y-RE & 5-FU/LV 5-FU/LV f 11/10 Colorectal Whole liver FLIC questionnaire, Spitzer index Baseline, 3-monthly (up to 36 months) No significant difference between arms Chow, 2014 (22) Y-RE & sorafenib - 29 HCC 20 patients whole liver, 9 patients lobar EQ-5D Index Baseline, every month until progression, 6-month intervals after progression EQ-5D index in BCLC g stage B decreased over time, while it increased in BCLC Stage C Wasan, 2017 (24) Y-RE & FOLFOX FOLFOX 554/549 Colorectal NA h EQ-5D-3L Index 0-1 Baseline, 2-3,6,12,24 months EQ-5D-3L index decreased over time in both groups, no clinically meaningful differences a : Of 50 included patients, 14 were evaluated for QoL. b : Transarterial chemoembolization. c : Hepatocellular carcinoma. d : 10 patients with missing baseline data were excluded from QoL analysis. e : 5-Fluorouracil. f : Leucovorin. g : Barcelona Clinic Liver Cancer. h : Not available.